Ignyta to Present at Ladenburg Thalmann Life Sciences Conference

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Ladenburg Thalmann Life Sciences Conference on Tuesday, September 29, 2015, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time) in New York, NY.

A webcast of the presentation will be available during the presentation in the Investors section of the company's website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a precision oncology biotechnology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The company’s goal with this Rx/Dx approach is to discover, develop and commercialize new drugs that target activated cancer genes and pathways for the customized treatment of cancer, as well as novel chemotherapeutics that can potentially provide additional benefit to cancer patients. It aims to achieve this goal by pairing its product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients who are most likely to benefit from the precisely targeted drugs the company develops. For more information, please visit: www.ignyta.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150922005029/en/

Ignyta, Inc.
Jacob Chacko, M.D.
CFO
858-255-5959
[email protected]

Source: Ignyta, Inc.

You May Also Be Interested In

• LithiumBank Announces Closing of Upsized Private Placement
• Wix.com Ltd. Notice of September 22, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• Hypercharge Reports First Quarter Fiscal 2027 Results & Management Change